INS and type 2 diabetes mellitus: Since type 2 diabetes is due to insufficient insulin production, inhibition of DPP-4, rather than insulin and its secretalogues, now becomes a well-tolerated therapeutic route for the treatment of type 2 diabetes because it improves plasma glucose metabolism efficiently and safely without hypoglycemia.